866-997-4948(US-Canada Toll Free)

Pulmonary Arterial Hypertension Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Therapeutic Area

No. of Pages : 134 Pages


Pulmonary Arterial Hypertension Pipeline Review, H2 2012

Global Markets Directs, 'Pulmonary Arterial Hypertension Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. Pulmonary Arterial Hypertension Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Pulmonary Arterial Hypertension.
  • A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Pulmonary Arterial Hypertension Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Pulmonary Arterial Hypertension 12
Pulmonary Arterial Hypertension Therapeutics under Development by Companies 14
Pulmonary Arterial Hypertension Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Pre-Clinical Stage Products 22
Comparative Analysis 22
Pulmonary Arterial Hypertension Therapeutics Products under Development by Companies 23
Pulmonary Arterial Hypertension Therapeutics Products under Investigation by Universities/Institutes 24
Companies Involved in Pulmonary Arterial Hypertension Therapeutics Development 25
Aradigm Corporation 25
United Therapeutics Corporation 26
GlaxoSmithKline plc 27
Mochida Pharmaceutical Co., Ltd. 28
Novartis AG 29
Actelion Ltd 30
Dong-A Pharmaceutical Co., Ltd. 31
Nippon Shinyaku Co., Ltd. 32
Bayer AG 33
Arena Pharmaceuticals, Inc. 34
Cytokinetics, Inc 35
Proteo, Inc. 36
Aires Pharmaceuticals, Inc. 37
Cardioxyl Pharmaceuticals, Inc. 38
Mondobiotech Holding AG 39
Asahi Kasei Pharma 40
Adeona Pharmaceuticals, Inc. 41
Ikaria Inc. 42
Northern Therapeutics, Inc. 43
Ascendis Pharma A/S 44
Pulmonary Arterial Hypertension Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
DasKloster-100001 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
nilotinib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
riociguat - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
APD-811 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
imatinib mesylate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
macitentan - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
fasudil - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
treprostinil SR - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Elafin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Cell Based Gene Therapy - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
treprostinil - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
carvedilol - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
selexipag - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
milrinone - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
warfarin sodium - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
vardenafil dihydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
DAPT - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
dexmedetomidine hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
sodium dichloroacetate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Reserpine + Fluoxetine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
glutamine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TXA-127 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
inhaled nitric oxide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
udenafil - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
CK-2018571 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
atorvastatin calcium - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Vindesine + Cisplatin - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ambrisentan - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
sodium nitrite - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
methylprednisolone - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
CK-2019165 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
eplerenone - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Nitroxyl Donor For PAH - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
sodium nitrite - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
anastrazole - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Synthetic Dna-Based Therapy - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
C-122 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
PLX-PAH - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Selegiline + PDE-5 Inhibitor - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
treprostinil - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
nitric oxide - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
tacrolimus - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Pulmonary Arterial Hypertension Therapeutics Drug Profile Updates 112
Pulmonary Arterial Hypertension Therapeutics Discontinued Products 123
Pulmonary Arterial Hypertension Therapeutics - Dormant Products 124
Pulmonary Arterial Hypertension Product Development Milestones 125
Featured News & Press Releases 125
Sep 19, 2012: Unigene And Tarix Pharma Announce Completion Of Feasibility Study Of TXA127 125
Sep 10, 2012: Actelion Announces Presentation Of Phase III Results Of Macitentan At CHEST 2012 126
Jun 29, 2012: Actelion Pharma Announces FDA Approval Of Supplemental New Drug Application For Second Generation VELETRI For Injection 126
Apr 30, 2012: Actelion's Macitentan Meets Primary Endpoint In Pivotal Phase III SERAPHIN Outcome Study In Patients With Pulmonary Arterial Hypertension 127
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Ventavis 128
Feb 21, 2012: Oral Treprostinil New Drug Application Accepted For Review By FDA 129
Feb 06, 2012: United Therapeutics Receives Paragraph IV Notice Letter For Remodulin 129
Jan 23, 2012: Ikaria Receives Orphan Drug Designation From FDA For Use Of Inhaled Nitric Oxide In Pulmonary Arterial Hypertension 129
Dec 27, 2011: United Therapeutics Receives French Regulatory Approval For Intravenous Remodulin For Treatment Of Pulmonary Arterial Hypertension 130
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 131

Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 134
Disclaimer 134

List of Table


Number of Products Under Development for Pulmonary Arterial Hypertension, H2 2012 12
Products under Development for Pulmonary Arterial Hypertension – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Aradigm Corporation, H2 2012 25
United Therapeutics Corporation, H2 2012 26
GlaxoSmithKline plc, H2 2012 27
Mochida Pharmaceutical Co., Ltd., H2 2012 28
Novartis AG, H2 2012 29
Actelion Ltd, H2 2012 30
Dong-A Pharmaceutical Co., Ltd., H2 2012 31
Nippon Shinyaku Co., Ltd., H2 2012 32
Bayer AG, H2 2012 33
Arena Pharmaceuticals, Inc., H2 2012 34
Cytokinetics, Inc, H2 2012 35
Proteo, Inc., H2 2012 36
Aires Pharmaceuticals, Inc., H2 2012 37
Cardioxyl Pharmaceuticals, Inc., H2 2012 38
Mondobiotech Holding AG, H2 2012 39
Asahi Kasei Pharma, H2 2012 40
Adeona Pharmaceuticals, Inc., H2 2012 41
Ikaria Inc., H2 2012 42
Northern Therapeutics, Inc., H2 2012 43
Ascendis Pharma A/S, H2 2012 44
Assessment by Monotherapy Products, H2 2012 45
Assessment by Combination Products, H2 2012 46
Assessment by Stage and Route of Administration, H2 2012 48
Assessment by Stage and Molecule Type, H2 2012 51
Pulmonary Arterial Hypertension Therapeutics – Drug Profile Updates 112
Pulmonary Arterial Hypertension Therapeutics – Discontinued Products 123
Pulmonary Arterial Hypertension Therapeutics – Dormant Products 124

List of Chart


Number of Products under Development for Pulmonary Arterial Hypertension, H2 2012 12
Products under Development for Pulmonary Arterial Hypertension Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 45
Assessment by Combination Products, H2 2012 46
Assessment by Route of Administration, H2 2012 47
Assessment by Stage and Route of Administration, H2 2012 48
Assessment by Molecule Type, H2 2012 49
Assessment by Stage and Molecule Type, H2 2012 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *